Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ACP1 | P24666 | 1/20 | 0.37 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.37 |
| ▸ | TTBK2 | Q6IQ55 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 7/20 | 0.35 |
| ▸ | RAB9A | P51151 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 3/20 | 0.35 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19781252 | 0.86 | GLA (0.41) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL22032818 | 0.84 | SYK (0.43) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL22032880 | 0.83 | ACP1 (0.41) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL15213071 | 0.79 | P2RX3 (0.43) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL19781521 | 0.79 | GLA (0.42) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL22072357 | 0.79 | GLA (0.44) | GLAACP1TTBK1TTBK2MAPT | |
| SCHEMBL22072401 | 0.74 | MAPT (0.46) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL19781774 | 0.74 | ACP1 (0.45) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL19781130 | 0.73 | ACP1 (0.42) | P2RX3GLAACP1TTBK1TTBK2 | |
| SCHEMBL4933031 | 0.72 | MAPT (0.57) | MAPTRAB9AKMT2AMEN1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-06-23 | — | — | US | disclosed |
| EP-3890731-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | Arisan Therapeutics, Inc. (US) | 2021-10-13 | — | — | EP | disclosed |
| WO-2020117794-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117794-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | ARISAN THERAPEUTICS, INC. (US) | 2020-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193038-A1 | COMPOUNDS FOR THE TREATMENT OF ARENAVIRUS INFECTION | HAVCR2, ZC3HAV1, CD4 | P2RX3 3679/4885GLA 527/4885ACP1 1539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.